Lamellar Biomedical partners with two leading Scottish universities to further optimise its LAMELLASOME™ Nucleic Acid delivery platform
Lamellar Biomedical Limited (Lamellar), an innovative biotechnology company, pioneering new approaches for the safe and effective transfer of functional nucleic acids, announces two research partnerships to further optimise its LAMELLASOME™ Nucleic Acid technology platform and its product manufacturing processes. The partnerships are with the University of Strathclyde and Edinburgh University. Lamellar believes its LAMELLASOME NAT (Nucleic Acid Transfer) technologywill play a key role in realising the potential of many of the nucleic acids in development, including siRNAs, microRNAs, mRNAs and plasmids, potentially revolutionising the treatment of numerous rare and intractable diseases.
Alec McLean, CEO of Lamellar Biomedical, said: “We are very pleased to announce these partnerships with two world-class research institutions. Together these research collaborations will contribute to further advancing our lead products for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and Cystic Fibrosis (CF). It will support our external collaborations with pharma in developing LAMELLASOME™ formulations for the safe and effective delivery of their novel nucleic acids across a spectrum of therapeutic areas.”
The first partnership, with Professor Yvonne Perrie (Chair in Drug Delivery) of the University of Strathclyde’s Institute of Pharmacy and Biomedical Sciences, is building upon pioneering work that will enable Lamellar to develop LAMELLASOME™ formulations optimised for the delivery of specific active substances.
The second partnership, with Edinburgh University’s Complex Fluid Partnership, allows Lamellar to test and optimise the biophysical properties of LAMELLASOME™ formulations regarding the ability to alter biological gels including CF sputum and bacterial biofilms to facilitate the delivery of pulmonary nucleic acids. This knowledge will also help us advance the development of other novel products for a range of therapeutic areas. Both projects are funded through the UK KTP program in conjunction with Lamellar for a duration of two years.
Margaret Courtney (Director for Manufacture at Lamellar) noted that“Lamellar are very excited about the award of these two partnerships that are designed to expand applications of the LAMELLASOME platform and further advance our manufacturing processes, with a focus on the reduction in formulation complexity, costs and time to market”.
Scotland has a strong and flourishing Pharma Services community, with a cluster of over 150 expert, innovative and ambitious companies employing over 9,000 skilled professionals, working together and ready to advance your drug development. Find out more about this, here.